About the Company
Celsion is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies and DNA-based therapies; and a platform for the development of nucleic acid vaccines currently focused on SARS-CoV2. The company's product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, is under investigator-sponsored development for several cancer indications. Celsion also has two feasibility stage platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. Both are novel synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $CLSN News
Imunon, Inc. (IMNN)
Company expects enrollment in Phase 1 proof-of-concept study of DNA-based vaccine technology to begin in the second quarter LAWRENCEVILLE, N.J., April 18, 2024 (GLOBE NEWSWIRE) -- IMUNON ...
IMNN: IND Application Submitted for Phase 1/2 Trial of Seasonal COVID-19 Vaccine…
Imunon, Inc. (NASDAQ:IMNN) is developing IMNN-101, which is a COVID-19 seasonal vaccine booster based on the company’s PlaCCine technology. It is a DNA vaccine that addresses a number of limitations ...
IMUNON Reports 2023 Financial Results and Provides Business Update
Conference Call Begins Today at 10:00 a.m. Eastern Time LAWRENCEVILLE, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on ...
Imunon, Inc. (IMNN) Q4 2023 Earnings Call Transcript
Good morning. My name is Dave, and I will be your operator today. At this time I would like to welcome you to Imunon 2023 Financial Results Conference Call. All lines have been placed on mute to ...
Imunon, Inc.: IMUNON's IND Application Cleared to Begin Human Testing of IMNN-101
Company expects enrollment in Phase 1 proof-of-concept study of DNA-based vaccine technology to begin in the second quarter LAWRENCEVILLE, N.J., April 18, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ ...
Viatris taps former Moderna executive Corinne Le Goff as new chief commercial officer
Viatris on Monday named Corinne Le Goff as the Canonsburg pharmaceutical company’s chief commercial officer. Le Goff takes ...
Imunon, Inc.: IMUNON Reports Compliance with Nasdaq Listing Requirements
IMUNON, Inc. (NASDAQ: IMNN) ("IMUNON" or the "Company"), a clinical-stage drug-development company focused on developing DNA-mediated immuno-oncology ...
IMUNON Reports 2023 Financial Results and Provides Business Update
Conference Call Begins Today at 10:00 a.m. Eastern Time LAWRENCEVILLE, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on ...
Imunon, Inc. (NASDAQ:IMNN) Q4 2023 Earnings Call Transcript
Imunon, Inc. beats earnings expectations. Reported EPS is $-0.52, expectations were $-0.59. Imunon, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter ...
Imunon Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
IMUNON Reports 2023 Financial Results and Provides Business Update
IMNN Imunon Inc IMUNON Reports 2023 Financial Results and Provides Business Update Conference Call Begins Today at 10:00 a.m. Eastern Time LAWRENCEVILLE, N.J., March 28, 2024 (GLOBE NEWSWIRE) ...
Loading the latest forecasts...